NanoViricides, Inc. (NNVC) Files FY2026 10-K; NV-387 Phase II Trials Begin Enrollment

NanoViricides filed its FY2026 Form 10-K and said NV-387 oral gummies Phase II trials for Mpox and Ebola in DRC began enrolling at end-Sept. 2026. Cash was approximately $2.79M at June 30, 2026; substantial doubt exists about going concern.Material DetailsContext by AI AnalystThis is early-to-mid s…